N
Newomics
Omics solutions enhancing precision medicine with high sensitivity, throughput, and robust plug-and-play design
About Newomics
Newomics specializes in providing advanced omics solutions tailored for precision medicine, focusing on high sensitivity and throughput. The company operates in the life sciences market, serving clients such as research institutions and pharmaceutical companies. Its core product, the UniESI ion source, is equipped with M3 emitters and MEA chips, enabling nano microflow LCMS applications. This technology significantly improves the analysis of small molecules, including lipids and glycans, by enhancing sensitivity and reducing in-source fragmentation. Newomics generates revenue through the sale of its proprietary instrumentation and consumables, catering to the growing demand for precise and efficient analytical tools in metabolomics and lipidomics. The business model is centered around product sales and customer support, ensuring robust performance and reliability for its users.
Source: Dealroom company dataAt a glance
- Founded
- 2018
- Headquarters
- Berkeley, United States
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Berkeley Catalyst Fund
Photon Fund
MSA Capital
LDV Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Newomics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Newomics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.